|Mr. Layton Patrick Mills||Founder, MD & Director||224.9k||N/A||N/A|
|Dr. Margaret Curtis||Head of Clinical Devel. and R&D||187.15k||N/A||N/A|
|Mr. Baden Maxwell Bowen||CFO & Company Sec.||N/A||N/A||N/A|
|Dr. Rayson Tan||Chief Scientific Officer & Member of Advisory Board||N/A||N/A||N/A|
CannPal Animal Therapeutics Limited, an animal health company, engages in the research and development of plant-based therapeutic products for pets in Australia. It develops CPAT-01, a cannabis-derived pharmaceutical product to provide veterinarians and pet owners to treat pain and inflammation in dogs. The company was incorporated in 2016 and is based in Double Bay, Australia.
CannPal Animal Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.